Evidence map›Paper›PMID 24082129›Full record

Trial reportProceedings of the National Academy of Sciences of the United States of America2013

Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.

Jiang-Han Wang, Wen-Lian Chen, Jun-Min Li, Song-Fang Wu, Tian-Lu Chen, Yong-Mei Zhu, Wei-Na Zhang, Yang Li, Yun-Ping Qiu, Ai-Hua Zhao and 18 more

Open access · bronzeAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Proceedings of the National Academy of Sciences of the United States of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 1 synthesis or guideline pooled it, 148 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Metabolomic insights into pathogenesis and therapeutic potential in adult acute lymphoblastic leukemia.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 9 institutions in 1 country.

Jiang-Han WangState Key Laboratory of Medical Genomics, Department of Hematology, Shanghai Institute of Hematology, Rui Jin Hospital affiliated with Shanghai Jiao Tong University School of Medicine and Key Laboratory of Systems Biomedicine of Ministry of Education, Shanghai Center for Systems Biomedicine, and Department of Biostatistics, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, People's Republic of China.
Wen-Lian Chen
Jun-Min Li
Song-Fang Wu
Tian-Lu Chen
Yong-Mei Zhu
Wei-Na Zhang
Yang Li
Yun-Ping Qiu
Ai-Hua Zhao
Jian-Qing Mi
Jie Jin
Yun-Gui Wang
Qiu-Ling Ma
He Huang
De-Pei Wu
Qin-Rong Wang
Yan Li
Xiao-Jing Yan
Jin-Song Yan
Jian-Yong Li
Shuai Wang
Xiao-Jun Huang
Bing-Shun Wang
Wei Jia
Yang Shen
Zhu Chen
Sai-Juan Chen
Shanghai Institute of Hematology · CNShanghai Jiao Tong University · CNZhejiang University · CNNanjing Medical University · CNSoochow University · CNChina Medical University · CNDalian Medical University · CNFirst Hospital of China Medical University · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 2-hydroxyglutarate (2-HG) has been reported to result from mutations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) genes and to function as an "oncometabolite." To evaluate the clinical significance of serum 2-HG levels in hematologic malignancies, acute myeloid leukemia (AML) in particular, we analyzed this metabolite in distinct types of human leukemia and lymphoma and established the range of serum 2-HG in appropriate normal control individuals by using gas chromatograph-time-of-flight mass spectrometry. Aberrant serum 2-HG pattern was detected in the multicenter group of AML, with 62 of 367 (17%) patients having 2-HG levels above the cutoff value (2.01, log2-transformed from 4.03 μg/mL). IDH1/2 mutations occurred in 27 of 31 (87%) AML cases with very high 2-HG, but were observed only in 9 of 31 (29%) patients with moderately high 2-HG, suggesting other genetic or biochemical events may exist in causing 2-HG elevation. Indeed, glutamine-related metabolites exhibited a pattern in favor of 2-HG synthesis in the high 2-HG group. In AML patients with cytogenetically normal AML (n = 234), high 2-HG represented a negative prognostic factor in both overall survival and event-free survival. Univariate and multivariate analyses confirmed high serum 2-HG as a strong prognostic predictor independent of other clinical and molecular features. We also demonstrated distinct gene-expression/DNA methylation profiles in AML blasts with high 2-HG compared with those with normal ones, supporting a role that 2-HG plays in leukemogenesis.

Indexed as

ChinaDisease-Free SurvivalDNA MethylationFemaleGene Expression Regulation, LeukemicGlutaratesHumansIsocitrate DehydrogenaseLeukemia, Myeloid, AcuteMaleMiddle AgedMutationSurvival Ratealpha-hydroxyglutarateGlutaratesIDH1 protein, humanIDH2 protein, humanIsocitrate Dehydrogenasebiomarkerprognosis

Identifiers

PMID24082129
PMCPMC3801077
OpenAlexW1971240883

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.